Skip to main content

Additional Articles by the Author

Select Drug Profiles, Payers' Guide

Erleada (Apalutamide) First Drug Approved by the FDA for Nonmetastatic Castration-Resistant Prostate Cancer

Select Drug Profiles, Payers' Guide

Libtayo (Cemiplimab-rwlc), a PD-1 Inhibitor, First Drug Approved by the FDA for Advanced Cutaneous Squamous-Cell Carcinoma

Select Drug Profiles, Payers' Guide

Xeljanz (Tofacitinib) Receives Expanded Indication, Becoming the First Oral JAK Inhibitor Approved for Ulcerative Colitis

Select Drug Profiles, Payers' Guide

Xermelo (Telotristat Ethyl), First-in-Class Tryptophan Hydroxylase Inhibitor, Approved for Carcinoid Syndrome Diarrhea

Select Drug Profiles, Payers' Guide

Tremfya (Guselkumab), First-in-Class IL-23 Blocker, Approved for the Treatment of Patients with Moderate-to-Severe Plaque Psoriasis

Select Drug Profiles, Payers' Guide

Siliq (Brodalumab) a New IL-17RA Antagonist Approved for Moderate-to-Severe Plaque Psoriasis

Select Drug Profiles, Payers' Guide

Nerlynx (Neratinib) First Extended Adjuvant Therapy Approved for HER2-Positive Breast Cancer

Select Drug Profiles, Payers' Guide

Idhifa (Enasidenib), First-in-Class IDH2 Inhibitor, Approved for Relapsed Acute Myeloid Leukemia with IDH2 Mutation

Select Drug Profiles, Payers' Guide

Gocovri (Amantadine) First Drug Approved for Dyskinesia in Patients with Parkinson’s Disease

Select Drug Profiles, Payers' Guide

Besponsa (Inotuzumab Ozogamicin) Approved for Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

1
2
3
4
5
6

Page 3 of 10
Results 21 - 30 of 98